Executive briefing · Basim Althani, MPH
Responsible Genomics Strategy
An executive framework for evaluating genomic services through utility, trust, quality, and operational readiness.
Utility before novelty
- Define the decision genomic information improves
- Assess evidence, clinical validity, utility, limitations, and alternatives
- State who benefits, under what conditions, and with what uncertainty
Trust by design
- Build informed choice, privacy, data stewardship, and uncertainty communication into the service
- Provide appropriate counseling and referral pathways
- Protect the ability to question or decline without disadvantage
End-to-end quality
- Treat acquisition, collection, laboratories, interpretation, delivery, counseling, and follow-up as one pathway
- Define quality standards, accountability, exceptions, and escalation
- Evaluate accessibility across information and service touchpoints
Readiness for scale
- Assess workforce, partners, technology, governance, economics, and capacity
- Use staged introduction and explicit readiness criteria
- Measure utility, experience, access, equity, quality, and unintended effects
Use boundary: This briefing is a general professional framework. It does not provide medical, legal, regulatory, accreditation, or investment advice. Application requires context-specific evidence and judgment.
Published and reviewed: 19 July 2026.
All executive briefings ↗